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 Abstract: 
Objectives – To undertake a cost-effectiveness analysis of outpatient uterine polypectomy compared 
with standard inpatient treatment under general anaesthesia.  
 Design – Economic evaluation carried out alongside the multi-centre, pragmatic, non-inferiority, 
randomised controlled Outpatient Polyp Treatment (OPT) trial. The UK National Health Service (NHS) 
perspective was used in the estimation of costs and the interpretation of results. 
Setting – 31 secondary care UK NHS hospitals between April 2008 and July 2011 
Participants - 507 women with abnormal uterine bleeding and hysteroscopically diagnosed endometrial 
polyps. 
Interventions – Outpatient uterine polypectomy versus standard inpatient treatment. Clinicians were 
free to choose the technique for polypectomy within the allocated setting. 
Main outcome measures - Patient reported effectiveness of the procedure determined by the women’s 
self-assessment of bleeding at six months, and QALY gains at six and 12 months. 
Results – Inpatient treatment was slightly more effective but more expensive than outpatient 
treatment, resulting in relatively high incremental cost effectiveness ratios. Intention to treat analysis of 
the base case at six months revealed that it cost an additional £ 9,421 per successfully treated patient in 
the inpatient group and £ 1,099,167 per additional QALY gained, when compared to outpatient 
treatment. At 12 months, these costs were £ 22,293 per additional effectively treated patient and £ 
445,867 per additional QALY gained respectively. 
Conclusions –Outpatient treatment of uterine polyps associated with abnormal uterine bleeding 
appears to be more cost-effective than inpatient treatment at willingness to pay thresholds acceptable 
to the NHS. 
Trial registration – ISRCTN: 65868569 
Key words- OPT trial, cost-effectiveness, Hysteroscopy, endometrial polyps, inpatient, outpatient. 
Tweetable abstract:  HTA funded OPT trial concluded that outpatient uterine polypectomy is cost 
effective compared with inpatient. 
Introduction 
Abnormal uterine bleeding (AUB) is one of the four most common reasons for consulting a general 
practitioner and accounts for 70% of all referrals to hospital gynaecology clinics1, making this complaint 
one of the commonest problems in gynaecology. A large proportion of health care resources in both 
primary care and hospital settings are used up in managing this condition1. Uterine polyps are one of the 
most prevalent pathologies underlying AUB being diagnosed in 20 to 30%2-4 of women with this 
presenting complaint. Until recently, conventional practice has been to undertake this simple procedure 
under general anaesthesia as an inpatient in hospital usually by blind uterine curettage (‘D&C’). Due to 
the need for inpatient hospital admission and general anaesthesia, this approach is associated with 
relatively heavy use of health care resources, with over 25,000 inpatient procedures being performed 
during 2011/12 in the United Kingdom5. Recent advances in endoscopic technology have now made it 
now possible to perform uterine polypectomy in a convenient outpatient setting without the need for 
hospital admission and anaesthesia. Furthermore, treatment can be carried out at the same time as 
diagnosis; the “see & treat” approach. However, the limitations of operating within the genital tract of a 
conscious patient may offset any apparent benefits over traditional practice. 
This economic evaluation was carried out alongside the Outpatient Polyp Treatment (OPT) trial which 
was a pragmatic multicenter randomized controlled non-inferiority study, comparing outpatient uterine 
polypectomy to inpatient treatment. The clinical findings of the trial are reported elsewhere 2. The 
primary objective of the study was to determine whether outpatient removal of uterine polyps was non-
inferior to inpatient polypectomy, the standard treatment offered by the National Health Service (NHS) 
in the UK. The primary end point was patient reported improvement in bleeding symptoms at six and 
twelve months. The aim of the economic evaluation was to determine the cost-effectiveness of 
outpatient polyp treatment compared with standard inpatient treatment. 
Methods 
Women who attended outpatient hysteroscopy clinics complaining of abnormal uterine bleeding and 
were found to have a uterine polyp were eligible to take part in the OPT trial. If they gave consent, they 
were randomised to either outpatient or inpatient polypectomy.  
The base case economic evaluation adopted the perspective of the NHS and took the form of cost-
effectiveness and cost utility analyses.. The outcomes of interest were patient self-assessment of 
treatment success at six and twelve months for the cost effectiveness analysis, and quality adjusted life 
years (QALYs) gained at one year for the cost-utility analysis. The costs and outcome measures used for 
this economic analysis were collected prospectively during the OPT trial. In addition, in order to explore 
societal perspective on costs, the out of pocket expenses incurred by the patients when attending for 
appointments and private time costs (including loss of time from work) were also collected using a 
separate questionnaire which was administered to the patients at randomisation and again on the day 
of procedure, if this was performed at a later date. 
All analyses were carried out using SAS 9.2®, Stata 12® and Microsoft Excel 2007®. The reporting of this 
analysis follows the Consolidated Health Economic Evaluation Reporting Standards (CHEERS)6. 
Costs: 
All costs in the analysis are in UK pounds (£), based on 2011/12 values. An a priori decision was made to 
use two separate methods to estimate the costs in this analysis:  The first method was to use the 
published standard sources of costs for NHS procedures (NHS Reference costs 2011-127 and Personal 
Social Services Resource Unit (PSSRU)8 Costs 2012) which was preferred for the base case analysis as it 
ensured that the results would be generalisable to all centres in the UK. The second method was to 
estimate the costs of inpatient and outpatient polypectomy by estimating the costs of the individual 
components of these procedures (bottom-up costing).  Health and Community Health Services (HCHS) 
pay and price indices were used to inflate costs, where appropriate8.  
Unit costs were attached to the cumulative resource use in each treatment group in order to calculate 
costs in both arms of the trial. Outpatient and inpatient polypectomy costs were estimated as per the 
NHS Reference costs (Table1). All patients recruited into the trial were assessed in an outpatient clinic 
and underwent an outpatient hysteroscopy where the uterine polyps were diagnosed.  Whilst most of 
the patients randomised to an outpatient procedure were treated on their initial visit, 28% were 
scheduled to attend for their treatment at a later clinic appointment.  All patients randomised to 
inpatient were assumed to have undergone pre-assessment in a nurse led clinic to ensure that they 
were suitable to receive general anaesthesia before being scheduled for their day-case inpatient 
procedure.   
Outcomes: 
Outcome data of interest within the trial were patient reported effectiveness of the procedure and also 
QALY gains at 6 and 12 months respectively. Within the OPT trial, the woman’s own assessment of 
bleeding symptoms was used to establish if the treatment had been successful. Those patients whose 
predominant complaint before the procedure was postmenopausal bleeding or intermenstrual bleeding 
were determined to have had a successful treatment if their abnormal bleeding had stopped. In women 
with heavy menstrual bleeding, treatment was successful if the patient reported that their bleeding had 
returned to an acceptable level following the procedure. 
All the patients in the trial were asked to complete EQ-5D (3L) questionnaires at baseline, 6 and 12 
months and the responses obtained were used as the basis for the cost utility analysis. 
 Assumptions: 
It was necessary to make the following pragmatic assumptions before the analysis could be carried out. 
• All the centres involved in the trial were assumed to have the same expertise and to have 
followed similar protocols in the management of these patients. 
• Only the related events (REs) that occurred within 1 year of the procedure and were deemed 
relevant to the polypectomy were included in the analysis. Related events included immediate 
complications of the procedure, all hysterectomies (irrespective of the indication), endometrial 
ablations and hysteroscopic procedures (excluding polypectomies) . Costs relating to further 
polyp related procedures, if any, were also estimated and stated separately to the REs. 
• The costs of procurement of the different endoscope camera systems used by participating 
centres in this study (Versascope™, Olympus™, Storz®) were assumed to be the same (at 
£50,500- see Table 2). The costs obtained by contacting the individual manufacturers of this 
equipment only varied from each other by around £1,000. 
Analysis: 
The base case analysis estimated costs and outcomes as per intention to treat. 
Cost effectiveness analysis (CEA) was carried out at 6 and 12 months based on the outcomes expressed 
in natural units which were estimated using responses obtained from patients to the question regarding 
effectiveness of the procedure. The results are expressed in terms of cost per additional patient 
successfully treated (based on alleviation of symptoms) at 6 months and 12 months. 
A cost utility analysis (CUA) was also carried out at 6 and 12 months and the results are expressed as 
additional cost incurred per QALY gained. Quality of life estimates were derived from the EQ5D 
responses provided by patients at baseline, 6 and 12 months by applying the standard UK tariff values. 
These estimates were then used to calculate total QALYs over 6 and 12 months for every individual in 
the study, using standard methods 9.  
. The results of the CUA are presented using cost-effectiveness acceptability curves (CEAC) to reflect 
sampling variation and uncertainties in the appropriate threshold cost-effectiveness value.  
Since the time frame of this economic evaluation was only one year, discounting was not necessary. 
Also, given that there was no significant difference in the baseline EQ5D scores (Table 3), a baseline 
adjustment was not performed during the analysis.  
All missing data were treated as missing at random and imputed using the Markov Chain Monte Carlo 
multiple imputation method. Bootstrapping was carried out to compare arithmetic means of the skewed cost 
and outcome data without making any assumptions regarding the sampling distributions (Table 3) 11 
A range of one-way sensitivity analyses were carried out to explore the robustness of the base case 
results to plausible variations during the uptake of these procedures in routine NHS use.  A deterministic 
sensitivity analysis (DSA) was carried out to assess the uncertainty associated with input parameters for 
the base case and  to widen the perspective. This technique estimates the effect of changing a single 
parameter (i.e., either cost or effectiveness) on the overall ICER obtained. The point estimates used for 
all the other parameters remain unchanged. In summary the following four options were considered. 
1. Using bottom-up costs for outpatient and inpatient polypectomy (DSA1): In the initial analyses, 
we only considered costs that were stipulated in the NHS reference costs. Whilst these costs are 
representative of the expenses incurred in the UK, in order to make the results more 
generalisable we calculated the costs of the procedures by breaking them down to the 
individual components involved and then adding up all the costs to obtain an overall cost (i.e. 
bottom up costing) and repeated the analyses. The estimated ‘bottom-up’ costs for the 
outpatient and inpatient procedures are outlined in Tables 4 and 5 respectively. 
2. Considering the out-of-pocket costs incurred by patients for the treatment (Societal perspective) 
(DSA2):  Since polypectomy is a quick procedure that is not expected to result in long standing 
illness or absence from work, the human capital approach method was used to estimate the 
societal costs of inpatient versus outpatient polypectomy. For those patients (and companions) 
who were in paid employment, the average hourly wage was calculated using the Office for 
National Statistics (ONS) estimates for the whole UK economy12 and an estimated 38.5 hours of 
work per week. Estimates used for leisure activities and house hold work were 42% and 57% of 
the net wage rate. These were derived from published literature 13. The cost of looking after 
relatives was assumed to be the same as that of household work (57% of net hourly wage). 
Where patients had taken paid time off work, these costs would have been incurred by the 
employers and were therefore included in the analysis. Those who were not involved in 
housework and were not in active employment (e.g. university students, retired persons) were 
assumed to incur the same costs as that for leisure activities. 
Private travel costs were derived from the automobile association (2012)14. These costs include 
total standing and running costs (fuel, parking, tolls, depreciation, wear and tear, tyre 
replacement, servicing etc.) and depend upon the annual mileage and type of car14. The cost of 
using public transport and car parking fees (where relevant) were directly obtained from the 
patients. Where time and mileage data were missing, these were assumed to be the same as the 
average for the entire group.  
3. Effect of ‘See and treat’ clinics (DSA3a and DSA3b): We re-analysed the data assuming that all 
patients (100%) and no patients (0%) were treated on the day of randomization (DSA3a and 
DSA3b respectively)  
4. Using new tariffs for outpatient polypectomy (DSA4): Previously there was a lack of incentive for 
‘see and treat’ outpatient clinics given that the remuneration was low. During the course of the 
study, the tariff for outpatient hysteroscopic procedure was increased and thus we used a 
higher cost (£ 1000) in a sensitivity analysis to predict the effect of this change. 
In addition, a probabilistic sensitivity analysis (PSA) of the base case was carried out to enable the 
simultaneous exploration of the uncertainties in the cost and outcome data. ,000 simulations were 
carried out using the Monte Carlo principle and the results were used to generate cost-effectiveness 
acceptability curves (CEACs), to demonstrates the probability of either intervention being cost effective 
at various willingness-to-pay thresholds. The results of these analyses are presented in terms of 
incremental cost effectiveness ratios (ICER) which reflect the additional cost per additional outcome of 
interest of outpatient versus inpatient treatment. 5 
Results 
The results for the base case analysis are presented in Table 6.  The point estimates of the mean costs 
incurred at 6 months on the outpatient and inpatient arm were £ 822 and £ 1482 respectively, a cost 
difference of approximately £ 660 (95% CI: 516.2-780.7). At the end of 12 months, the costs increased 
slightly to £ 938 and £ 1606 respectively, a cost difference of approximately £ 669 (95% CI: 517.0-833.1). 
The point estimates for difference in QALY were 0.0006 and 0.001 at 6 and 12 months respectively. The 
proportion of patients who reported improvement in symptoms following polypectomy was 0.74 and 
0.81 at 6 months and 0.82 and 0.85 at 12 months in the outpatient and inpatient arms respectively. 
Thus, the difference in effectiveness at 6 and 12 months was 0.07 (95% CI: -0.15- -0.01) and 0.03 (95% 
CI: -0.09-0.04) 
 The incremental cost effectiveness ratio (ICER) for the inpatient arm compared to outpatient arm at 6 
months was £ 1,099,167 per QALY, meaning that each additional QALY gained in the inpatient cost an 
additional £ 1,099,167. At 12 months the ICER was £ 445,867 per QALY. In the inpatient arm for each 
patient that had their symptoms successfully resolved, it cost an extra £9,421 compared to the 
outpatient arm. By twelve months post treatment this cost increased to £ 22,293. (Table 6). 
Deterministic Sensitivity analysis:  
Holding the outcome data constant, one-way deterministic sensitivity analyses were carried out by 
changing the cost data. As shown in Table 7, inpatient polypectomy remained more expensive than 
outpatient treatment in all of the scenarios considered.  
Probabilistic Sensitivity Analysis (PSA): 
Probabilistic sensitivity analysis showed that the likelihood of outpatient polypectomy being effective 
(when EQ5D estimates are used as outcome of interest) is similar to that of inpatient treatment. Figures 
1 and 2 clearly demonstrate that whilst inpatient treatment is definitely more expensive than the 
outpatient treatment, the difference in effectiveness is more uncertain. The mean cost differences 
between the groups as per the PSA were £ 661 and £ 658 at 6 and 12 months respectively (the inpatient 
costs are higher). The corresponding values for QALY difference were 0.0002 and 0.0005 respectively at 
6 and 12 months (the inpatient QALY gain is higher).  This suggests that the effects of the treatment on 
costs and QALYs beyond 6 months, as expected, are minimal. 
The CEACs shown in Figure 3 demonstrate that since both treatments are equally effective, the cheaper 
treatment will be the preferred procedure at lower willingness to pay (WTP) thresholds. Indeed, 
inpatient and outpatient therapy only start to become equally cost effective at a WTP threshold of £ 
90,000. 
Discussion 
Main findings: 
We found that inpatient polypectomy was more expensive than outpatient treatment and marginally 
more effective, resulting in slightly higher point estimates of self-reported effectiveness and QALY 
values at six and 12 months. The differences in costs and outcomes between these procedures were 
fairly constant at these time points reflecting that the treatment has very little long term (i.e. beyond six 
months) implications for health and resource use. The ICERs obtained by cost-effectiveness and cost-
utility analyses were very high, reflecting the equivalence in effectiveness between these procedures.  
Whilst the mean estimates of outcomes appear to favour inpatient treatment, it is important to note 
that there was considerable uncertainty around these point estimates.  This was explored further using 
probabilistic sensitivity analysis, clearly demonstrating that whilst outpatient therapy is definitely 
cheaper than inpatient treatment, the effectiveness estimates are uncertain with the likelihood of 
effectiveness being roughly equal in both groups at 6 and 12 months (Fig. 1 and 2). 
A range of cost variations which were considered plausible during the implementation of these 
treatment pathways within the NHS were considered. However, these did not make a difference to the 
conclusions from the base case analysis. It is notable that the bottom-up costs estimated for outpatient 
and inpatient procedure during this analysis were quite close to the tariffs from the NHS reference costs 
(Tables 4 and 5). 
Although this was a non-inferiority trial and there was equivalence in effectiveness whilst costs were 
different between the groups (the so called ‘weak dominance’ situation as postulated by Drummond et 
al15), a cost minimization analysis was not considered appropriate since this would not provide adequate 
information regarding the uncertainty in the estimates.  This was better estimated by carrying out a full 
cost effectiveness and probabilistic sensitivity analyses 16. 
Strengths and limitations: 
The OPT trial is the first, large randomised prospective study to estimate the costs and effectiveness of 
inpatient versus outpatient treatment for uterine polyps in women with abnormal uterine bleeding.  
Economic data in this study were collected prospectively alongside clinical outcome data enabling 
accurate estimation of the costs and outcomes. In addition, robust techniques were used to account for 
data uncertainty, missing data and the skewness of data. Although the base case analysis is mainly 
relevant to the UK, the sensitivity analyses enhance the generalisability of the findings of the study. 
It was assumed for the purposes of this analysis that all the participating UK centres had similar 
expertise with regards to inpatient and outpatient treatments, but it is possible that centres where 
outpatient therapy has been offered on the NHS for many years perform the procedure better when 
compared to those with relatively inexperienced clinicians. It was not considered appropriate to explore 
in detail the heterogeneity across centres using approaches such as a random effects model. Such an 
approach is unlikely to be illuminating because of the additional limitations associated with trying to 
incorporate a large number of centres who recruited a small number of patients into a model as this 
would lead to model convergence problems. In addition, in the interests of simplicity and clarity, the 
economic analysis did not explore the differences in costs and outcomes in subgroups of patients 
considered within the trial (e.g. pre vs. post-menopausal; different age groups etc.). The clinical 
effectiveness results for these groups were roughly similar2 and it was, therefore, felt that no further 
value could be added by extending the analysis. 
Training costs were not included in this analysis.  However, hysteroscopy is now routinely performed in 
the outpatient setting by most gynaecologists and performing an outpatient polypectomy will need 
relatively little further training for those already proficient with the diagnostic procedure. In addition, it 
is envisaged that all current clinical trainees (and future consultants) will have acquired the skills 
necessary for this procedure during their training. 
Interpretation (in light of other evidence) 
To our knowledge, this is the only study to prospectively estimate and compare the costs and outcomes 
of inpatient versus outpatient treatment for this common condition17. An earlier economic analysis, 
conducted alongside  a single centre, retrospective audit of 60 patients had identified the potential cost-
effectiveness of polyp treatment in an outpatient setting 18.  
 
Conclusion 
In conclusion, outpatient polypectomy appears to be more cost-effective than the inpatient approach to 
uterine polypectomy at currently acceptable willingness to pay thresholds for the NHS. Thus, for the 
many women presenting with abnormal uterine bleeding due to uterine polyps, the outpatient hospital 
or community treatment setting should be recommended as the best use of limited NHS resources. 
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Table 1: Costs allocated to outpatient and inpatient polypectomy 
 
Resource 
 
Details1 Cost (£) 
Outpatient Costs   
Initial outpatient 
clinic 
Consultant gynaecologist led face to face clinic; non-
admitted 
146 
Hysteroscopy Initial outpatient hysteroscopy for diagnosis of 
polyps; MA21Z 
197 
Follow-up outpatient 
clinic 
Gynaecology: Follow-up appointment consultant led; 
face to face; no admission 
112 
Outpatient 
polypectomy 
procedure 
Outpatient procedure; MA12Z 188 
 Total cost 
 
643 
Inpatient costs 
 
  
Initial outpatient 
clinic 
Consultant gynaecologist led face to face clinic; non-
admitted 
146 
Hysteroscopy Initial outpatient hysteroscopy for diagnosis of 
polyps; MA21Z 
197 
Pre-op assessment 
clinic 
Gynaecology: First appointment non-consultant  led; 
face to face; no admission 
118 
Daycase 
polypectomy 
procedure 
 
Daycase procedure; MA12Z 995 
 Total cost 
 
1456 
1 All costs are derived from the NHS reference costs 2011/12 
Costs are for patients who had diagnostic polypectomy at their first appointment and treatment at a second 
appointment.  Where patients are seen and treated in the same clinic, the costs will be £531 (i.e excluding follow up 
clinic costs. 
 
 
 
 
 
 
Table 2: Equipment procurement costs 
 
Equipment Procurement 
Cost (£)* 
equipment 
lifespan 
 in years 
Annutisation 
factor^ 
Annuitised 
costs (£)^^ 
times re-used 
per week 
Sterilisation/ 
maintenance 
per 
patient(£) 
Cost per patient (£) 
Cervical Speculum 2 0 (disposable) 0 2 0 0 2 
Grasping Forceps** 662.5 5 0.842 773.7 5 0.2 0.8 
Hysteroscope 5,400 10 0.71 6,493 5 1.5 4 
Electrode 212** 0 (disposable) 0 0 0 0 212 
Hysteroscope camera 
system (Olympus / 
Versascope / Storz) 
50,500 5 0.71 59,268 20 14.1 25.5 
Total cost for equipment 56,776.5   237.5 
 
Grasping forceps (reusable 3 prong forceps for large polyp and foreign body retrieval length 1650mm opening diameter 20mm)- procurement cost per 
year = 662.5; Annuitised cost = 773.7; Cost per year = 773.7/5=154.7; cost per patient = 154.7/260 = 0.6; Including sterilisation costs = 0.6+0.2 = 0.8 
** costs inflated from 2000 prices  129 to 2011 using the PSSRU inflation indices ^ at 3.5% discount rate over the lifespan of the equipment ;  
^annuitisation costs (E) calculated as per 147 :  E=[K-(S/(1+r)n)]/A(n,r);  where K is the procurement cost, S is the re-sale value, r is the discount factor 
(3.5%) and n is the estimated lifespan of the equipment. A is the annuitisation factor that is estimated from the values of n and r (adapted from 
Drummond, M.F. et al, Methods for the Economic Evaluation of Health Care Programmes. Third ed. 2005, Oxford: Oxford University Press) 
Table 3: Outcome data at baseline, 6 and 12 months 
 
 
 
*results shown as mean; standard deviation 
*numbers in brackets signify percentage of data missing/ unavailable for analysis 
 
 
 Outpatient Inpatient 
Base case analysis (ITT): N=254 N=253 
Effectiveness 6 months  0.73; 0.45 (10.2%)* 0.80; 0.40 (16.6%)* 
Effectiveness 12 months 0.81; 0.39 (11.4%) 0.83; 0.38 (15.4%) 
EQ5D baseline  0.78; 0.25 (4.7%) 0.79; 0.27 (8.3%) 
EQ5D 6 months 0.87; 0.22 (9.5%) 0.87; 0.2 (16.6%) 
EQ5D 12 months 0.86; 0.25 (10.6%) 0.86; 0.24 (13.4%) 
 Table 4: Bottom up costs for outpatient polypectomy 
 
 
Resource Cost per patient (£) Source Details 
Initial clinic 86 PSSRU 30 min of gynaecological 
consultant time including 
training cost 
Hysteroscopy 239.6 Critchley et al Inflated to 2011/12 rates 
from 2004 costs^ 
Nurse (Band 6) 21.50 PSSRU 30 min 
Consultant  73.5 PSSRU 30 min of gynaecological 
consultant time 
Procedure costs 237.5 Estimated See table 3 
Local Anaesthetic costs 0.35 Estimated Derived based on usage 
data from the trial 
Total cost 658.45   
 
*A further cost of £ 86 was added for patients who did not have treatment on the day of initial assessment. 
                  ^Inflated using PSSRU hospital and community health services (HCHS) index. 
 
 
 
 
 
 
 
 Table 5: Bottom up costs for inpatient polypectomy 
Resource Cost per patient 
(£) 
Source Details 
Initial assessment:    
Initial clinic 86 PSSRU 30 mins of consultant time incl 
training costs 
Hysteroscopy 239.6 Critchley et al Inflated to 2011/12 rates from 
2004 costs* 
Pre-assessment clinic 
 
78.8 PSSRU 45 min of Band 6 nurse time – with 
patient contact 
ECG 61 NHS ref Monitoring Electrocardiogram 
EA47Z 
Blood tests 5 Local NHS 
laboratory 
Full blood count (£ 2) and urea and 
electrolytes (£ 3) 
Procedure costs:    
Day case admission cost 673 NHS ref Unit price; Day case admission 
Nurse assessment (Band 6) 10.75 PSSRU Assessment for admission; 15 min 
Anaesthetist 24.5 PSSRU Consultant; 10 min pre-op 
assessment 
Porter costs 5.25 PSSRU Transfer to operating theatre 30 
min 
Nurse cost (Band 5) 17.5 PSSRU Transfer to operating theatre  30 
min 
Equipment cost 237.5 Derived See Table 3 
GA drugs 17.5 Estimated Derived based on usage data from 
the trial  
GA equipment 116.8 Estimated Derived based on usage data from 
the trial 
Post- operative    
Recovery ward 52.5 PSSRU 30 mins nurse time (Band 6); 
patient contact 
Porter costs 5.25 PSSRU Transfer to ward; 15 min 
Nurse cost 17.5 PSSRU Transfer to ward; 30 min 
Discharge 14.75 PSSRU Trainee doctor 5 min; Staff nurse 
15 min (Band 5) 
Overall cost  1,663.2   
*Inflated using PSSRU hospital and community health services (HCHS) index. 
Table 6: Results of the base case analysis: 
 
 Outpatient^ 
    n=254 
Inpatient^ 
  n=253 
difference* 
ITT analysis: (6 months)   
Overall cost  822.1 (832.3) 1481.6 (680.5) -659.5 [65.7] 
Overall QALY  0.41 (0.09) 0.41 (0.09) -0.0006 [0.01] 
Patient reported 
Effectiveness  
0.74 (0.44) 0.81 (0.39) -.07 [.04] 
 
ICER (Δ cost /                
Δ effectiveness) 
 
£9,421 per extra patient who feels better with inpatient treatment 
ICER (Δ cost/Δ QALY) £1,099,167 per QALY gained on the inpatient arm 
 
ITT analysis: (12 months)   
Overall cost  937.6 (971.4) 1606.3 (861.5) -668.8 [82.9] 
Overall QALY  0.83 (0.19) 0.84 (0.18) -0.001 [0.02] 
Patient reported 
Effectiveness 
0.82 (0.39) 0.85 (0.36) -.03 [0.31] 
ICER (Δ cost /                
Δ effectiveness) 
£22,293 per additional patient who feels better with inpatient 
treatment 
 
ICER (Δ cost/Δ QALY) £668,800 per additional QALY gained on the inpatient arm 
 
 
 
 
 
 
 
Table 7: Results of the Deterministic Sensitivity Analyses (DSA) 
 
 
ITT analysis: 
DSA1 (Bottom up costs) DSA-2 (Out of pocket costs) DSA-3a  (see and treat at 
same appt for all OP) 
DSA-3b (see then treat for 
all OP) 
DSA-4 (New OP tariffs) 
6 months 12 months 6 months 12 months 6 months 12 months 6 months 12 months 6 months 12 months 
 
Cost difference^ 
 
 
-719.8 [68.8] 
 
-664.2 [83.2] 
 
-671.7 [66.2] 
 
-618.6 [84.3] 
 
-673.5 [66.8] 
 
-620.4 [80.0] 
 
-584.5 [65.7] 
 
-531.4 [79.0] 
 
-294.1 [63.0] 
 
-241.0 
[76.2] 
ICER* 10,282.9 22,140 9,595.7 20,620 9,621.4 20,680 8,350 17,713.3 4,201.4 8,033.3 
Cost/ QALY 1,199,666.7 664,200 1,119,500 618,600 1,122,500 620,400 974,166.7 531,400 490,166.7 241,000 
 
^The negative values of cost difference imply that the cost of inpatient therapy is higher than that of outpatient treatment. 
^Differences have been estimated using bootstrapping techniques so that the uncertainty around the mean cost estimates can be accounted for. The results are shown 
as mean difference [standard error of the difference] 
*ICER here refers to cost difference/ difference in self-reported effectiveness at 6 and 12 months respectively. Effectiveness and QALY difference are assumed 
constant for DSA1 through to DSA4. 
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Figure 1: Probabilistic  Sensitivity Analysis (PSA) for Outpatient vs Inpatient treatment (6 
months) 
 
 
Figure 2: Probabilistic  Sensitivity Analysis (PSA) Outpatient vs Inpatient treatment (12 
months) 
 
Figure 1 and 2: PSA analysis which simultaneously represents uncertainty in cost and QALY values at 6 and 12 
months. The x and y axes represent the incremental effectiveness and cost of OP treatment compared with IP 
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treatment respectively. Most of the values fall in the lower right and left quadrants demonstrating that 
inpatient therapy is more expensive than outpatient treatment. The equal distribution between the left and 
right quadrants suggests that there is considerable uncertainty regarding the effectiveness of one treatment 
over the other (based on QALY values). In other words, the effectiveness of both treatments is similar. 
 
Figure 3: Cost effectiveness acceptability curve (CEAC) Outpatient vs Inpatient treatment 
 
Figure 3: A CEAC illustrates the uncertainty around the cost effectiveness estimates by demonstrating the 
likelihood of an intervention being cost effective at a given cost threshold compared to the proposed 
alternative. In this case, given that the likelihood of effectiveness of both treatments is roughly the same, the 
cheaper treatment is considered most cost-effective at baseline.  
 
 
 
